Indeed, a trial of cediranib and selumetinib has recently been initiated in solid tumors (NCT01364051) but may be more effective if directed towards melanoma patients with both BRAFV600E mutation and elevated KDR/PDGFRα/β expression. Here, PDGFRA is linked to melanoma.